Covance Dallas Clinical Research Unit
Dallas, Texas, 75247, United States
NCT Number: NCT02336347
To compare pharmacokinetics (PK) of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) to AVP-923 (dextromethorphan hydrobromide [DM]/Q) at steady state.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Dallas, Texas, 75247, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: deuterated (d6)-dextropmethorphan/quindine sulfate
Other names: dextromethorphan/quinidine
Time frame: 8 days
Time frame: 8 days
Time frame: 8 days
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, 2-way Crossover Study Comparing AVP-786 With AVP-923
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07502417
Healthy Volunteer
Grayslake, Illinois, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06717269
Healthy Volunteer
Lincoln, Nebraska, United States
View Trial DetailsNCT00001367
Healthy Volunteer, Nervous System Disease
Bethesda, Maryland, United States
View Trial Details